Atezolizumab in Treating Patients With Recurrent BCG-Unresponsive Non-muscle Invasive Bladder Cancer



Status:Recruiting
Healthy:No
Age Range:18 - Any
Updated:4/6/2019
Start Date:February 7, 2017
End Date:February 28, 2020

Use our guide to learn which trials are right for you!

Phase II Trial of Atezolizumab in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

This phase II trial studies how well atezolizumab works in treating patients with non-muscle
invasive bladder cancer that has come back and has not responded to treatment with Bacillus
Calmette-Guerin (BCG). Immunotherapy with monoclonal antibodies, such as atezolizumab, may
help the body's immune system attack the cancer, and may interfere with the ability of tumor
cells to grow and spread.

PRIMARY OBJECTIVES:

I. To estimate complete response at 25 weeks after registration for those with a carcinoma in
situ (CIS) component and to evaluate event-free survival at 18 months in patients with
BCG-unresponsive high-risk non-muscle invasive bladder cancer (Ta/T1/CIS) treated with
atezolizumab.

SECONDARY OBJECTIVES:

I. To estimate event-free survival at 18 months for the subset of patients with papillary
cancer (Ta/T1).

II. To estimate progression-free survival, cystectomy-free survival, bladder cancer-specific
survival, overall survival in all patients.

ADDITIONAL OBJECTIVES:

I. To estimate the level of agreement between local and central pathology review in terms of
recurrence (for all patients) and complete response (for the CIS subset).

II. To identify markers that predict response to atezolizumab in the CIS population and that
are associated with event-free survival (EFS) in patients with Ta/T1/CIS BCG-unresponsive
non-muscle invasive bladder cancer. The following markers will be tested: expression of PD-L1
and CD8 by immunohistochemistry (IHC); expression of immune signatures by ribonucleic acid
(RNA)-sequencing (RNA-seq); peripheral immune response by mass cytometry (CyTOF) and
TruCulture.

OUTLINE:

Patients receive atezolizumab intravenously (IV) over 60 minutes on day 1. Treatment repeats
every 21 days for up to 17 courses (51 weeks) in the absence of disease progression or
unacceptable toxicity.

After completion of study treatment, patients are followed up every 12 weeks for 2 years and
then every 24 weeks for 3 years.

Inclusion Criteria:

- Patients must have histologically proven, recurrent, non-muscle invasive urothelial
carcinoma of the bladder within 60 days prior to registration; the carcinoma must be
stage T1 high-grade, stage CIS, or stage Ta high-grade

- Patients with mixed urothelial carcinoma and a glandular and/or squamous component
will be eligible for the trial, but the presence of other histologic variants, pure
adenocarcinoma, or pure squamous cell carcinoma, or pure squamous carcinoma in situ
will make a patient ineligible

- Patients must have had all visible tumor resected completely within 60 days prior to
registration; CIS disease is not expected to be completely excised; all patients must
have tumor tissue from the histologic diagnosis of recurrence available for central
pathology review submission; failure to submit these materials will make the patient
ineligible for this study

- Patients must have had cystoscopy confirming no visible papillary tumor within 21 days
prior to registration; (CIS disease is not expected to have been completely excised);
if the transurethral resection of bladder tumor (TURBT) or bladder biopsy falls within
21 days of registration it will fulfill this criterion

- Patients must have had urine cytology within 21 days prior to registration; cytology
for patients with CIS component is not expected to be negative for malignant cells; if
the cytology for male patients with only Ta/T1 disease in the absence of CIS is
positive for malignant cells, patient must have had a biopsy of the prostatic urethra
within the previous six months

- All patients with T1 urothelial carcinoma at study entry must undergo re-TURBT within
60 days prior to registration, and must have evidence of uninvolved muscularis propria
in the pathologic specimen from either the first or the second TURBT; tissue from the
re-resection must be submitted for central review in addition to the tissue from the
first TURBT; the TURBT that identified the recurrent T1 disease may have taken place
more than 60 days prior to registration but not more than 120 days; patients with high
grade Ta or CIS do not require a re-TURBT, but if this is performed at the discretion
of the treating physician, the second TURBT must be within 60 days of registration;
there is no requirement for muscularis propria in the specimen of Ta/CIS patients, but
the tissue from the first and second TURBTs must be submitted for central review; if a
patient with Ta/T1 disease undergoes repeat TURBT, the patient will be stratified as
having CIS if there is CIS on either TURBT

- Patients must not have had urothelial carcinoma in the prostate urethra within the
previous 24 months or muscle invasive urothelial carcinoma of the bladder at any time;
patients with prior urothelial carcinoma in the upper urinary tract within the
previous 24 months will only be eligible if they had =< T1 carcinoma and were treated
with nephroureterectomy; patients must have a computed tomography (CT) or magnetic
resonance imaging (MRI) (including CT-intravenous pyelogram [IVP], CT-urogram or
MR-urogram) of the abdomen and pelvis to rule out upper tract malignancy and
intra-abdominal metastases within 90 days prior to registration; if a patient cannot
tolerate intravenous contrast, a retrograde pyelogram should be performed within 90
days prior to registration

- Patients must be deemed unfit for radical cystectomy by the treating physician, or the
patient must refuse radical cystectomy, which is considered standard of care for these
patients; the reason for patients not to undergo cystectomy will be clearly documented

- Patients must be BCG-unresponsive; a patient is BCG-unresponsive if they meet one or
more of the following criteria:

- Patient has persistent or recurrent high-grade Ta/CIS urothelial carcinoma after
completing therapy with at least induction BCG (>= 5 doses) and first round
maintenance (>= 2 doses) or second induction BCG (>= 2 doses); both rounds of BCG
must have been administered within a 12 month period; these patients must have
either had high-grade Ta tumors and did not achieve a disease-free state for more
than 6 months following last dose of BCG, or they had CIS and did not achieve a
CR; S1605 registration must occur within 9 months of the last dose of BCG.

- If a patient does not meet these criteria only because the last dose of BCG
was more than 9 months ago, the patient may become eligible if he/she shows
histologically proven high-grade recurrence after an additional round of
induction or maintenance BCG (>= 3 doses) within 9 months prior to
registration

- Patient has persistent or recurrent high grade T1 urothelial carcinoma after
completing therapy with at least induction BCG (>= 5 doses); patients with
recurrent high grade T1 urothelial carcinoma after additional rounds of BCG will
also be eligible, but one round of maintenance therapy or a second induction is
not a pre-requisite for these patients. Trial registration must occur within 9
months of the last dose of BCG

- If a patient does not meet these criteria only because the last dose of BCG
was more than 9 months ago, the patient may become eligible if he/she shows
histologically proven high grade recurrence after an additional round of
induction or maintenance BCG (>= 3 doses) within 9 months prior to
registration

- Patient achieves disease-free state at 6 month time point (i.e., complete
response; presence of only low-grade tumor at this timepoint is still considered
complete response) after induction and maintenance (or second round of induction)
BCG but later experiences a high-grade Ta/T1recurrence (with or without
concomitant CIS) within 6 months after the last dose of BCG or recurrent CIS (in
absence of concomitant Ta/T1 tumor) within 12 months after the last BCG dose; the
time of eligibility is measured from the last dose of BCG to the time of disease
recurrence; the patient must be registered on the trial within 60 days of this
recurrence, or within 60 days of a re-TURBT if indicated

- All adverse events associated with any prior surgery and intravesical therapy must
have resolved to grade =< 2 prior to registration

- Patients must not have had prior systemic chemotherapy for bladder cancer or systemic
immunotherapy, including, but not limited to interferon alfa-2b, high dose interleukin
2 (IL-2), pegylated interferon (PEG-IFN), PD-1, anti-PD-L1, intra-tumoral; patients
must not have had vaccine therapies within 6 weeks prior to registration; patients
must not have received or be planning to receive any of the prohibited therapies
during protocol treatment; prior intravesical administration of chemotherapy,
interferon, Vicinium (VB4-485), BC-819 or Instiladrin (rAd-interferon-alpha/Syn3) is
allowed if all other criteria are met and the last administration was >= 30 days
before registration

- Patients must not be planning to receive concomitant other biologic therapy, radiation
therapy, intravesical chemotherapy, surgery, or other anti-cancer therapy while on
this protocol

- Patients must not have received any prior radiation to the bladder for bladder cancer

- Patients must not have received treatment with systemic immunosuppressive medications
(including, but not limited to, prednisone, cyclophosphamide, azathioprine,
methotrexate, thalidomide, and anti-tumor necrosis factor [anti-TNF] agents) within 4
weeks prior to registration; exceptions: (1) patients may have received acute, low
dose, systemic immunosuppressant medications (e.g., a one-time dose of dexamethasone
for nausea); (2) the use of inhaled corticosteroids and mineralocorticoids (e.g.,
fludrocortisone) for patients with orthostatic hypotension or adrenocortical
insufficiency is allowed

- Patients must not have received a live, attenuated vaccine within 4 weeks before
registration or anticipation that such a live, attenuated vaccine will be required
during the study and up to 5 months after the last dose of atezolizumab

- Influenza vaccination should be given during influenza season only (approximately
October to March); patients must not receive live, attenuated influenza vaccine
within 4 weeks prior to cycle 1, day 1 or at any time during the study

- Patients must not require treatment with a RANKL inhibitor (e.g. denosumab) who cannot
discontinue it before treatment with atezolizumab

- Absolute neutrophil count (ANC) >= 1,500 microliter (mcL) (within 42 days prior to
registration)

- Platelets >= 100,000/mcL (within 42 days prior to registration)

- Hemoglobin >= 9 g/dL (within 42 days prior to registration)

- Total bilirubin =< 1.5 x institutional upper limit of normal (IULN) (except Gilbert's
syndrome, who must have a total bilirubin < 3.0 mg/dL) (within 42 days prior to
registration)

- Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) =< 2 x IULN (within
42 days prior to registration)

- Serum creatinine =< 1.5 ULN OR measured or calculated creatinine clearance >= 30
mL/min (within 42 days prior to registration)

- Patients must have Zubrod performance status =< 2

- Patients must have a baseline electrocardiograph (ECG) performed within 42 days prior
to registration

- Patient must not have history of idiopathic pulmonary fibrosis, pneumonitis (including
drug induced), organizing pneumonia (i.e., bronchiolitis obliterans, cryptogenic
organizing pneumonia, etc.), or evidence of active pneumonitis

- Patients must not have an active infection requiring oral or IV antibiotics within 14
days prior to registration; patients receiving prophylactic antibiotics (e.g., for
prevention of a urinary tract infection or chronic obstructive pulmonary disease) are
eligible

- Patients must not have severe infections within 28 days prior to registration,
including but not limited to hospitalization for complications of infection,
bacteremia, or severe pneumonia

- Patients must not have active autoimmune disease that has required systemic treatment
in past two years (i.e., with use of disease modifying agents, corticosteroids or
immunosuppressive drugs); replacement therapy (e.g., thyroxine, insulin, or
physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency,
etc.) is not considered a form of systemic treatment; autoimmune diseases include, but
are not limited to, systemic lupus erythematosus, rheumatoid arthritis, inflammatory
bowel disease, vascular thrombosis associated with antiphospholipid syndrome,
Wegener's granulomatosis, Sjogren's syndrome, Bell's palsy, Guillain-Barre syndrome,
multiple sclerosis, autoimmune thyroid disease, vasculitis, or glomerulonephritis

- Patients must not have undergone prior allogeneic bone marrow transplantation or prior
solid organ transplantation

- Patient must not have active tuberculosis

- Patients must not have active hepatitis B (chronic or acute) or active hepatitis C
infection

- Patients with past or resolved hepatitis B infection (defined as having a
negative hepatitis B surface antigen [HBsAg] test and a positive anti-HBc
[antibody to hepatitis B core antigen] antibody test) are eligible

- Patients positive for hepatitis C virus (HCV) antibody are eligible only if
polymerase chain reaction (PCR) is negative for HCV RNA

- Patients positive for human immunodeficiency virus (HIV) are eligible only if they
have all of the following:

- A stable regimen of highly active anti-retroviral therapy (HAART)

- No requirement for concurrent antibiotics or antifungal agents for the prevention
of opportunistic infections

- A CD4 count above 250 cells/mcL and an undetectable HIV viral load on standard
PCR-based tests

- No other prior malignancy is allowed except, for the following: adequately treated
basal cell or squamous cell skin cancer, in situ cervical cancer, adequately treated
stage I or II cancer from which the patient is currently in complete remission, or any
other cancer from which the patient has been disease free for five years

- Patients must not be pregnant or nursing due to the potential teratogenic side effects
of the protocol treatment; administration of atezolizumab may have an adverse effect
on pregnancy and poses a risk to the human fetus, including embryo-lethality; women of
child-bearing potential and men must agree to use adequate contraception (hormonal or
barrier method of birth control; abstinence) prior to study entry, for the duration of
study participation, and for 5 months (150 days) after the last dose of study agent; a
woman is considered to be of "reproductive potential" if she has had menses at any
time in the preceding 12 consecutive months; should a woman become pregnant or suspect
she is pregnant while she or her partner is participating in this study, she should
inform her treating physician immediately

- Due to the potential drug reaction with atezolizumab, patients must not be known to be
allergic to Chinese hamster egg or ovaries

- Patients must be offered the opportunity to participate in specimen banking for future
studies, to include translational medicine studies

- Patients must be informed of the investigational nature of this study and must sign
and give written informed consent in accordance with institutional and federal
guidelines

- As a part of the oncology patient enrollment network (OPEN) registration process the
treating institution's identity is provided in order to ensure that the current
(within 365 days) date of institutional review board approval for this study has been
entered in the system
We found this trial at
262
sites
1309 W 17th Street
Sioux Falls, South Dakota 57104
(605) 328-8000
Principal Investigator: Preston D. Steen
Phone: 605-312-3320
Sanford Cancer Center-Oncology Clinic Sanford Health is an integrated health system headquartered in the Dakotas...
?
mi
from
Sioux Falls, SD
Click here to add this to my saved trials
666 Elm Street
Buffalo, New York 14263
(716) 845-2300
Principal Investigator: Qiang J. Li
Phone: 800-767-9355
Roswell Park Cancer Institute Welcome to Roswell Park Cancer Institute (RPCI), America's first cancer center...
?
mi
from
Buffalo, NY
Click here to add this to my saved trials
301 University Blvd
Galveston, Texas 77555
(409) 772-1011
Principal Investigator: Stephen B. Williams
Phone: 409-772-1950
University of Texas Medical Branch Established in 1891 as the University of Texas Medical Department,...
?
mi
from
Galveston, TX
Click here to add this to my saved trials
401 College Street
Richmond, Virginia 23298
(804) 828-0450
Principal Investigator: Asit K. Paul
Phone: 888-823-5923
Virginia Commonwealth University Massey Cancer Center Founded in 1974, VCU Massey Cancer Center is a...
?
mi
from
Richmond, VA
Click here to add this to my saved trials
60 Crittenden Blvd # 70
Rochester, New York 14642
(585) 275-2121
Principal Investigator: Paul M. Barr
Phone: 585-275-5830
University of Rochester The University of Rochester is one of the country's top-tier research universities....
?
mi
from
Rochester, NY
Click here to add this to my saved trials
4502 Medical Drive
San Antonio, Texas 78284
(210) 567-7000
Principal Investigator: Chethan Ramamurthy
Phone: 210-450-3800
University of Texas Health Science Center at San Antonio The University of Texas Health Science...
?
mi
from
San Antonio, TX
Click here to add this to my saved trials
1000 36th Street
Vero Beach, Florida 32960
Principal Investigator: James M. Grichnik
Phone: 772-563-4673
?
mi
from
Vero Beach, FL
Click here to add this to my saved trials
98-1079 Moanalua Road
'Aiea, Hawaii 96701
Principal Investigator: Jared D. Acoba
Phone: 808-486-6000
?
mi
from
'Aiea, HI
Click here to add this to my saved trials
5301 McAuley Drive
Ann Arbor, Michigan 48197
734-712-3456
Principal Investigator: Tareq Al Baghdadi
Phone: 734-712-3671
Saint Joseph Mercy Hospital St. Joseph Mercy Ann Arbor Hospital is a 537-bed teaching hospital...
?
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
1625 Maple Lane
Ashland, Wisconsin 54806
Principal Investigator: Bret E. Friday
Phone: 218-786-3308
?
mi
from
Ashland, WI
Click here to add this to my saved trials
Atlanta, Georgia 30322
Principal Investigator: Bradley C. Carthon
Phone: 404-778-1868
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
12605 East 16th Avenue
Aurora, Colorado 80045
720-848-0000
Principal Investigator: Elizabeth R. Kessler
Phone: 720-848-0650
University of Colorado Hospital, Site Top medical professionals, superior medicine and progressive change make University...
?
mi
from
Aurora, CO
Click here to add this to my saved trials
2000 Ogden Ave
Aurora, Illinois 60504
(630) 978-6200
Principal Investigator: Priyank P. Patel
Phone: 630-978-6212
Rush - Copley Medical Center Rush-Copley is proud to be the leading provider of health...
?
mi
from
Aurora, IL
Click here to add this to my saved trials
Aventura, Florida 33180
Principal Investigator: Michael A. Schwartz
Phone: 888-823-5923
?
mi
from
Aventura, FL
Click here to add this to my saved trials
3325 Pocahontas Road
Baker City, Oregon 97814
Principal Investigator: Tareq Al Baghdadi
Phone: 541-523-8112
?
mi
from
Baker City, OR
Click here to add this to my saved trials
401 North Broadway
Baltimore, Maryland 21287
410-955-5000
Principal Investigator: Trinity J. Bivalacqua
Phone: 410-955-8804
Johns Hopkins University-Sidney Kimmel Cancer Center The name Johns Hopkins has become synonymous with excellence...
?
mi
from
Baltimore, MD
Click here to add this to my saved trials
300 N. Seventh St.
Bismarck, North Dakota 58501
(701) 323-6000
Principal Investigator: Preston D. Steen
Phone: 701-323-5760
Sanford Bismarck Medical Center Whether your stay in our hospital is one day for same...
?
mi
from
Bismarck, ND
Click here to add this to my saved trials
1505 Eastland Drive
Bloomington, Illinois 61701
309-662-2102
Principal Investigator: Bryan A. Faller
Phone: 309-243-3605
Illinois CancerCare-Bloomington Illinois CancerCare, P.C. is a comprehensive practice treating patients withcancer andblood diseases. Our...
?
mi
from
Bloomington, IL
Click here to add this to my saved trials
Boise, Idaho 83706
Principal Investigator: Benjamin T. Marchello
Phone: 734-712-3671
?
mi
from
Boise, ID
Click here to add this to my saved trials
100 E Idaho St
Boise, Idaho 83712
(208) 381-2711
Principal Investigator: Gary E. Goodman
Saint Luke's Mountain States Tumor Institute For more than 100 years, St. Luke
?
mi
from
Boise, ID
Click here to add this to my saved trials
Bonne Terre, Missouri 63628
Principal Investigator: Bryan A. Faller
Phone: 314-996-5569
?
mi
from
Bonne Terre, MO
Click here to add this to my saved trials
Boston, Massachusetts 02118
Principal Investigator: Gretchen A. Gignac
Phone: 617-638-8265
?
mi
from
Boston, MA
Click here to add this to my saved trials
7575 Grand River Avenue
Brighton, Michigan 48114
Principal Investigator: Tareq Al Baghdadi
Phone: 734-712-3671
?
mi
from
Brighton, MI
Click here to add this to my saved trials
7575 Grand River Avenue
Brighton, Michigan 48114
Principal Investigator: Tareq Al Baghdadi
Phone: 734-712-3671
?
mi
from
Brighton, MI
Click here to add this to my saved trials
Burlington, Wisconsin 53105
Principal Investigator: Antony Ruggeri
Phone: 414-302-2304
?
mi
from
Burlington, WI
Click here to add this to my saved trials
201 E Nicollet Blvd
Burnsville, Minnesota 55337
(952) 892-2000
Principal Investigator: David M. King
Phone: 952-993-1517
Fairview Ridges Hospital Fairview Ridges Hospital is a 150-bed, Level III Trauma Care facility, offering...
?
mi
from
Burnsville, MN
Click here to add this to my saved trials
3123 Medical Dr
Caldwell, Idaho 83605
Principal Investigator: Benjamin T. Marchello
Phone: 734-712-3671
?
mi
from
Caldwell, ID
Click here to add this to my saved trials
210 W Walnut St
Canton, Illinois 61520
309-647-5240
Principal Investigator: Bryan A. Faller
Phone: 309-243-3605
Illinois CancerCare - Canton Illinois CancerCare is one of the largest private oncology and hematology...
?
mi
from
Canton, IL
Click here to add this to my saved trials
1600 South Canton Center Road
Canton, Michigan 48188
Principal Investigator: Tareq Al Baghdadi
Phone: 734-712-3671
?
mi
from
Canton, MI
Click here to add this to my saved trials
1600 South Canton Center Road
Canton, Michigan 48188
Principal Investigator: Tareq Al Baghdadi
Phone: 734-712-3671
?
mi
from
Canton, MI
Click here to add this to my saved trials
211 Saint Francis Drive
Cape Girardeau, Missouri 63703
573-331-3000
Principal Investigator: Bryan A. Faller
Phone: 573-334-2230
Saint Francis Medical Center Saint Francis Medical Center is a 282-bed facility serving more than...
?
mi
from
Cape Girardeau, MO
Click here to add this to my saved trials
789 Mt Auburn Rd
Cape Girardeau, Missouri 63703
(573) 519-4725
Principal Investigator: Bryan A. Faller
Phone: 573-651-5550
Southeast Cancer Center SoutheastHEALTH is a far-reaching network of providers and facilities including Southeast Hospital...
?
mi
from
Cape Girardeau, MO
Click here to add this to my saved trials
401 North Hooper Street
Caro, Michigan 48723
Principal Investigator: Tareq Al Baghdadi
Phone: 734-712-3671
?
mi
from
Caro, MI
Click here to add this to my saved trials
160 S Adams St
Carthage, Illinois 62321
(217) 357-6877
Principal Investigator: Bryan A. Faller
Phone: 309-243-3605
Illinois CancerCare - Carthage Illinois CancerCare, P.C. is a comprehensive practice treating patients withcancer andblood...
?
mi
from
Carthage, IL
Click here to add this to my saved trials
Centralia, Illinois 62801
Principal Investigator: Bryan A. Faller
Phone: 217-876-4740
?
mi
from
Centralia, IL
Click here to add this to my saved trials
Chadds Ford, Pennsylvania 19317
Principal Investigator: Gregory A. Masters
Phone: 302-623-4500
?
mi
from
Chadds Ford, PA
Click here to add this to my saved trials
505 S Plummer Ave
Chanute, Kansas 66720
(620) 431-7580
Principal Investigator: Shaker R. Dakhil
Phone: 316-268-5374
Cancer Center of Kansas, PA - Chanute Dr. H.E. Hynes founded Cancer Center of Kansas,...
?
mi
from
Chanute, KS
Click here to add this to my saved trials
3110 MacCorkle Avenue Southeast
Charleston, West Virginia 25304
Principal Investigator: Steven J. Jubelirer
Phone: 304-388-9944
?
mi
from
Charleston, WV
Click here to add this to my saved trials
14650 East Old US Highway 12
Chelsea, Michigan 48118
Principal Investigator: Tareq Al Baghdadi
Phone: 734-712-3671
?
mi
from
Chelsea, MI
Click here to add this to my saved trials
775 South Main Street
Chelsea, Michigan 48118
Principal Investigator: Tareq Al Baghdadi
Phone: 734-712-3671
?
mi
from
Chelsea, MI
Click here to add this to my saved trials
303 East Superior Street
Chicago, Illinois 60611
Principal Investigator: Joshua J. Meeks
Phone: 312-695-1301
?
mi
from
Chicago, IL
Click here to add this to my saved trials
12961 27th Ave
Chippewa Falls, Wisconsin 54729
715-738-3700
Principal Investigator: Seth O. Fagbemi
Phone: 800-782-8581
Marshfield Clinic - Chippewa Center The 15,000 square foot Lake Hallie Center provides urgent care...
?
mi
from
Chippewa Falls, WI
Click here to add this to my saved trials
5680 Bow Pointe Drive
Clarkston, Michigan 48346
Principal Investigator: Tareq Al Baghdadi
Phone: 734-712-3671
?
mi
from
Clarkston, MI
Click here to add this to my saved trials
31500 Telegraph Road
Clarkston, Michigan 48346
Principal Investigator: Tareq Al Baghdadi
Phone: 734-712-3671
?
mi
from
Clarkston, MI
Click here to add this to my saved trials
Clinton, North Carolina 28328
Principal Investigator: Nagesh H. Jayaram
Phone: 919-587-9077
?
mi
from
Clinton, NC
Click here to add this to my saved trials
Clinton, South Carolina 29325
Principal Investigator: Jeffrey K. Giguere
Phone: 844-651-1233
?
mi
from
Clinton, SC
Click here to add this to my saved trials
1 Hospital Dr
Columbia, Missouri 65212
(573) 882-2100
Principal Investigator: Puja Nistala
Phone: 573-882-7440
University of Missouri-Ellis Fischel Ellis Fischel Cancer Center's team of physician specialists and other trained...
?
mi
from
Columbia, MO
Click here to add this to my saved trials
Danville, Illinois 61832
Principal Investigator: Priyank P. Patel
Phone: 800-446-5532
?
mi
from
Danville, IL
Click here to add this to my saved trials
29653 Anchor Cross Boulevard
Daphne, Alabama 36526
Principal Investigator: Connie D. Uzel
Phone: 251-607-5281
?
mi
from
Daphne, AL
Click here to add this to my saved trials
Dayton, Ohio 45415
Principal Investigator: Howard M. Gross
Phone: 937-832-1093
?
mi
from
Dayton, OH
Click here to add this to my saved trials
Dayton, Ohio 45415
Principal Investigator: Howard M. Gross
Phone: 937-775-1350
?
mi
from
Dayton, OH
Click here to add this to my saved trials
Decatur, Georgia 30033
Principal Investigator: Wayne B. Harris
Phone: 404-321-6111
?
mi
from
Decatur, GA
Click here to add this to my saved trials
2300 N Edward St
Decatur, Illinois 62526
(217) 876-8121
Principal Investigator: Bryan A. Faller
Phone: 217-876-4740
Decatur Memorial Hospital An American flag bearing only 48 stars waved above Decatur Memorial Hospital...
?
mi
from
Decatur, IL
Click here to add this to my saved trials
210 West McKinley Avenue
Decatur, Illinois 62526
Principal Investigator: Bryan A. Faller
Phone: 217-876-4740
?
mi
from
Decatur, IL
Click here to add this to my saved trials
Denver, Colorado 80205
Principal Investigator: Alexander Menter
Phone: 303-764-5056
?
mi
from
Denver, CO
Click here to add this to my saved trials
2020 Central Ave
Dodge City, Kansas 67801
(620) 227-2488
Principal Investigator: Shaker R. Dakhil
Phone: 316-268-5374
Cancer Center of Kansas, PA - Dodge City Dr. H.E. Hynes founded Cancer Center of...
?
mi
from
Dodge City, KS
Click here to add this to my saved trials
Duluth, Minnesota 55805
Principal Investigator: Bret E. Friday
Phone: 218-786-3308
?
mi
from
Duluth, MN
Click here to add this to my saved trials
Duluth, Minnesota 55805
Principal Investigator: Bret E. Friday
Phone: 888-203-7267
?
mi
from
Duluth, MN
Click here to add this to my saved trials
Duluth, Minnesota 55805
Principal Investigator: Bret E. Friday
Phone: 888-203-7267
?
mi
from
Duluth, MN
Click here to add this to my saved trials
Duluth, Minnesota 55805
Principal Investigator: Homam Alkaied
Phone: 888-823-5923
?
mi
from
Duluth, MN
Click here to add this to my saved trials
Easley, South Carolina 29640
Principal Investigator: Jeffrey K. Giguere
Phone: 864-241-6251
?
mi
from
Easley, SC
Click here to add this to my saved trials
East Lansing, Michigan 48824
Principal Investigator: Jatin Rana
Phone: 517-975-9547
?
mi
from
East Lansing, MI
Click here to add this to my saved trials
Eau Claire, Wisconsin 54701
Principal Investigator: Seth O. Fagbemi
Phone: 800-782-8581
?
mi
from
Eau Claire, WI
Click here to add this to my saved trials
6401 France Ave S
Edina, Minnesota 55435
(952) 924-5000
Principal Investigator: David M. King
Phone: 952-993-1517
Fairview Southdale Hospital Fairview Health Services is an award-winning nonprofit health care system based in...
?
mi
from
Edina, MN
Click here to add this to my saved trials
Edmonton, Alberta
Principal Investigator: Scott A. North
Phone: 780-432-8500
?
mi
from
Edmonton,
Click here to add this to my saved trials
Effingham, Illinois 62401
Principal Investigator: Bryan A. Faller
Phone: 217-876-4740
?
mi
from
Effingham, IL
Click here to add this to my saved trials
Effingham, Illinois 62401
Principal Investigator: Priyank P. Patel
Phone: 800-446-5532
?
mi
from
Effingham, IL
Click here to add this to my saved trials
700 West Central
El Dorado, Kansas 67042
(316) 889-0099
Principal Investigator: Shaker R. Dakhil
Phone: 316-889-0099
Cancer Center of Kansas, PA - El Dorado Dr. H.E. Hynes founded Cancer Center of...
?
mi
from
El Dorado, KS
Click here to add this to my saved trials
155 E. Brush Hill Road
Elmhurst, Illinois 60126
(331) 221-1000
Principal Investigator: Brian C. Myre
Phone: 630-758-5460
Elmhurst Memorial Hospital When it comes to medical care, you have a lot of options....
?
mi
from
Elmhurst, IL
Click here to add this to my saved trials
1202 East Locust Street
Emmett, Idaho 83617
Principal Investigator: Tareq Al Baghdadi
Phone: 208-367-7954
?
mi
from
Emmett, ID
Click here to add this to my saved trials
101 S Major St
Eureka, Illinois 61530
309-467-2371
Principal Investigator: Bryan A. Faller
Phone: 309-243-3605
Illinois CancerCare - Eureka Illinois CancerCare is one of the largest private oncology and hematology...
?
mi
from
Eureka, IL
Click here to add this to my saved trials
801 Broadway North
Fargo, North Dakota 58122
Principal Investigator: Preston D. Steen
Phone: 701-323-5760
?
mi
from
Fargo, ND
Click here to add this to my saved trials
Fargo, North Dakota 58122
Principal Investigator: Preston D. Steen
Phone: 701-234-6161
?
mi
from
Fargo, ND
Click here to add this to my saved trials
165 North University Avenue
Farmington, Utah 84025
Principal Investigator: William T. Lowrance
Phone: 888-424-2100
?
mi
from
Farmington, UT
Click here to add this to my saved trials
Flint, Michigan 48503
Principal Investigator: Tareq Al Baghdadi
Phone: 810-762-8400
?
mi
from
Flint, MI
Click here to add this to my saved trials
302 Kensington Avenue
Flint, Michigan 48503
Principal Investigator: Tareq Al Baghdadi
Phone: 810-762-8200
?
mi
from
Flint, MI
Click here to add this to my saved trials
302 Kensington Ave
Flint, Michigan 48503
(810) 762-8490
Principal Investigator: Tareq Al Baghdadi
Phone: 888-762-8675
Genesys Hurley Cancer Institute Bringing the most advanced cancer treatment services, technologies and programs available...
?
mi
from
Flint, MI
Click here to add this to my saved trials
Fond Du Lac, Wisconsin 54937
Principal Investigator: Antony Ruggeri
Phone: 414-302-2304
?
mi
from
Fond Du Lac, WI
Click here to add this to my saved trials
Fort Scott, Kansas 66701
(620) 223-8589
Principal Investigator: Shaker R. Dakhil
Phone: 620-223-8589
Cancer Center of Kansas - Fort Scott Dr. H.E. Hynes founded Cancer Center of Kansas,...
?
mi
from
Fort Scott, KS
Click here to add this to my saved trials
1600 Southwest Archer Road
Gainesville, Florida 32610
Principal Investigator: Paul L. Crispen
Phone: 352-273-8010
?
mi
from
Gainesville, FL
Click here to add this to my saved trials
3315 N Seminary St
Galesburg, Illinois 61401
309-344-9269
Principal Investigator: Bryan A. Faller
Phone: 309-243-3605
Illinois CancerCare - Galesburg Illinois CancerCare, P.C. is a comprehensive practice treating patients withcancer andblood...
?
mi
from
Galesburg, IL
Click here to add this to my saved trials
Germantown, Wisconsin 53022
Principal Investigator: Antony Ruggeri
Phone: 414-302-2304
?
mi
from
Germantown, WI
Click here to add this to my saved trials
Goldsboro, North Carolina 27534
Principal Investigator: Nagesh H. Jayaram
Phone: 919-587-9077
?
mi
from
Goldsboro, NC
Click here to add this to my saved trials
2700 Wayne Memorial Dr
Goldsboro, North Carolina 27534
(919) 736-1110
Principal Investigator: James N. Atkins
Phone: 919-731-6687
Wayne Memorial Hospital Wayne Memorial Hospital, an affiliate of Wayne Health Corporation, is home to...
?
mi
from
Goldsboro, NC
Click here to add this to my saved trials
Grafton, Wisconsin 53024
Principal Investigator: Antony Ruggeri
Phone: 414-302-2304
?
mi
from
Grafton, WI
Click here to add this to my saved trials
1117 29th St S
Great Falls, Montana 59405
(406) 771-7300
Principal Investigator: Benjamin T. Marchello
Phone: 406-969-6060
Benefis Healthcare- Sletten Cancer Institute Benefis Hospitals has 516 beds at its two campuses (that...
?
mi
from
Great Falls, MT
Click here to add this to my saved trials
2845 Greenbrier Rd
Green Bay, Wisconsin 54311
(920) 288-8000
Principal Investigator: Antony Ruggeri
Phone: 414-302-2304
Aurora BayCare Medical Center Aurora BayCare Medical Center is a 167-bed, full-service hospital serving the...
?
mi
from
Green Bay, WI
Click here to add this to my saved trials
Greenville, South Carolina 29605
Principal Investigator: Jeffrey K. Giguere
Phone: 864-241-6251
?
mi
from
Greenville, SC
Click here to add this to my saved trials
Greenville, South Carolina 29605
Principal Investigator: Jeffrey K. Giguere
Phone: 864-241-6251
?
mi
from
Greenville, SC
Click here to add this to my saved trials
701 Grove Rd
Greenville, South Carolina 29605
(864) 455-7000
Principal Investigator: Jeffrey K. Giguere
Phone: 864-241-6251
Greenville Memorial Hospital Greenville Memorial Medical Campus is a regional referral center for the diagnosis...
?
mi
from
Greenville, SC
Click here to add this to my saved trials
Greenville, South Carolina 29615
Principal Investigator: Jeffrey K. Giguere
Phone: 864-241-6251
?
mi
from
Greenville, SC
Click here to add this to my saved trials
Greenwich, Connecticut 06830
Principal Investigator: Beverly J. Drucker
Phone: 203-863-3698
?
mi
from
Greenwich, CT
Click here to add this to my saved trials
Greer, South Carolina 29650
Principal Investigator: Jeffrey K. Giguere
Phone: 864-241-6251
?
mi
from
Greer, SC
Click here to add this to my saved trials
24800 SE Stark St
Gresham, Oregon 97030
(503) 674-1122
Principal Investigator: Jacqueline Vuky
Phone: 503-413-2150
Legacy Mount Hood Medical Center Legacy Mount Hood Medical Center, East County's full-service community hospital,...
?
mi
from
Gresham, OR
Click here to add this to my saved trials
2220 Canterbury Drive
Hays, Kansas 67601
785.623.5000
Principal Investigator: Eugene K. Lee
Phone: 785-623-5774
Hays Medical Center Hays Medical Center is a private, not-for-profit hospital formed by the 1991...
?
mi
from
Hays, KS
Click here to add this to my saved trials
Henderson, Nevada 89052
Principal Investigator: John A. Ellerton
Phone: 702-384-0013
?
mi
from
Henderson, NV
Click here to add this to my saved trials
Hines, Illinois 60141
?
mi
from
Hines, IL
Click here to add this to my saved trials
Honolulu, Hawaii 96813
Principal Investigator: Jared D. Acoba
Phone: 808-524-6115
?
mi
from
Honolulu, HI
Click here to add this to my saved trials
Honolulu, Hawaii 96813
Principal Investigator: Jared D. Acoba
Phone: 808-532-0315
?
mi
from
Honolulu, HI
Click here to add this to my saved trials
Honolulu, Hawaii 96813
Principal Investigator: Charles J. Rosser
Phone: 808-586-2979
?
mi
from
Honolulu, HI
Click here to add this to my saved trials
Honolulu, Hawaii 96817
Principal Investigator: Jared D. Acoba
Phone: 808-531-8521
?
mi
from
Honolulu, HI
Click here to add this to my saved trials